ES2389751T3 - Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias - Google Patents

Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias Download PDF

Info

Publication number
ES2389751T3
ES2389751T3 ES08842581T ES08842581T ES2389751T3 ES 2389751 T3 ES2389751 T3 ES 2389751T3 ES 08842581 T ES08842581 T ES 08842581T ES 08842581 T ES08842581 T ES 08842581T ES 2389751 T3 ES2389751 T3 ES 2389751T3
Authority
ES
Spain
Prior art keywords
disease
level
activity
mice
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08842581T
Other languages
English (en)
Spanish (es)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ES2389751T3 publication Critical patent/ES2389751T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
ES08842581T 2007-10-24 2008-10-15 Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias Active ES2389751T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
ES2389751T3 true ES2389751T3 (es) 2012-10-31

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08842581T Active ES2389751T3 (es) 2007-10-24 2008-10-15 Un nuevo biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias
ES12002502.8T Active ES2532361T3 (es) 2007-10-24 2008-10-15 CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12002502.8T Active ES2532361T3 (es) 2007-10-24 2008-10-15 CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20100059902A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2503338T3 (enExample)
ES (2) ES2389751T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2503338T3 (enExample)
PT (2) PT2201376E (enExample)
SI (2) SI2503338T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
DK2956772T3 (en) * 2013-02-14 2018-08-13 Faron Pharmaceuticals Oy A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB201715115D0 (en) 2017-09-19 2017-11-01 Univ London Queen Mary Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
AU7310496A (en) * 1995-10-13 1997-04-30 Imperial College Of Science, Technology And Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1608400B1 (en) * 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
CA2657576C (en) * 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
JP2011501176A (ja) 2011-01-06
EP2503338B1 (en) 2014-12-24
PL2503338T3 (pl) 2015-06-30
CY1116089T1 (el) 2017-02-08
SI2503338T1 (sl) 2015-06-30
EP2201376A4 (en) 2011-03-23
KR20160029869A (ko) 2016-03-15
EP2503338A2 (en) 2012-09-26
JP2012159514A (ja) 2012-08-23
HRP20150181T1 (hr) 2015-06-19
WO2009053523A1 (en) 2009-04-30
JP4982610B2 (ja) 2012-07-25
KR20100059902A (ko) 2010-06-04
US20100209942A1 (en) 2010-08-19
ES2532361T3 (es) 2015-03-26
EP2201376B1 (en) 2012-08-08
PT2201376E (pt) 2012-08-20
CY1113403T1 (el) 2016-06-22
PL2201376T3 (pl) 2013-01-31
FI20070795A0 (fi) 2007-10-24
DK2503338T3 (en) 2015-03-09
PT2503338E (pt) 2015-03-05
JP5619810B2 (ja) 2014-11-05
HRP20120743T1 (hr) 2012-10-31
EP2201376A1 (en) 2010-06-30
EP2503338A3 (en) 2013-03-13
SI2201376T1 (sl) 2012-09-28
DK2201376T3 (da) 2012-10-15
CA2702635A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
ES2532361T3 (es) CD73 como biomarcador para monitorizar el desarrollo de enfermedades y evaluar la eficacia de terapias
Sood et al. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies
Heper et al. Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock
ES2718731T3 (es) Métodos, dispositivos y kits para detectar o monitorizar la lesión renal aguda
Hartmann et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein
US20150355180A1 (en) Differential Expression of Novel Protein Markers for the Diagnosis and Treatment of Eosinophilic Esophagitis
Mukama et al. A highly sensitive and specific lateral flow aptasensor for the detection of human osteopontin
US20130217033A1 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
van Golen et al. The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
ES2911270T3 (es) Composición para diagnosticar enfermedades infecciosas o complicaciones infecciosas mediante el uso de triptofanil-arnt sintetasa y método para detectar el marcador de diagnóstico
Cibor et al. Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease.
Covarrubias-Zambrano et al. Optical biosensing of markers of mucosal inflammation
ES2851798T3 (es) Método y dispositivo para discriminar entre infecciones virales y bacterianas
BR112019024966A2 (pt) Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal
ES2306080T3 (es) Procedimiento para el diagnostico de septicemina mediante determinacion selectiva de la concentracion de superoxidodismutasa cu/zn (sod cu/zn) en muestras de pacientes.
Veldeman et al. Levels of bioactive adrenomedullin in plasma and cerebrospinal fluid in relation to delayed cerebral ischemia in patients after aneurysmal subarachnoid hemorrhage: A prospective observational study
ES2697299B2 (es) Biomarcadores diferenciales de asma
Ikeoka et al. Interleukin-6 produced in subcutaneous adipose tissue is linked to blood pressure control in septic patients
Çelik et al. Cytokine release syndrome in Crimean-Congo hemorrhagic fever: can IL-1 receptor antagonist levels be a guide in its treatment?
Yang et al. Total and double-stranded DNA-specific immunoglobulin E in bronchoalveolar lavage fluid of children with human adenovirus pneumonia
Kurt et al. Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients
Al-Habib et al. Inflammatory protein levels in asthmatic bronchitis: A study in the Duhok population, Iraq
Lewandowska-Polak et al. 2 Lack of Association Between Aspirin-Triggered 15-Hydroxyeicosatetraenoic Acid Release and Mast Cell/Eosinophil Activation in Nasal Polyps From Aspirin-Sensitive Patients
Hafez et al. Serum soluble CD93 as a biomarker of asthma exacerbation in children